JPWO2022186311A1 - - Google Patents
Info
- Publication number
- JPWO2022186311A1 JPWO2022186311A1 JP2023503935A JP2023503935A JPWO2022186311A1 JP WO2022186311 A1 JPWO2022186311 A1 JP WO2022186311A1 JP 2023503935 A JP2023503935 A JP 2023503935A JP 2023503935 A JP2023503935 A JP 2023503935A JP WO2022186311 A1 JPWO2022186311 A1 JP WO2022186311A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021034026 | 2021-03-04 | ||
| JP2021146833 | 2021-09-09 | ||
| PCT/JP2022/009003 WO2022186311A1 (ja) | 2021-03-04 | 2022-03-02 | 化合物及び放射性標識化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022186311A1 true JPWO2022186311A1 (https=) | 2022-09-09 |
| JPWO2022186311A5 JPWO2022186311A5 (https=) | 2025-02-21 |
Family
ID=83155351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503935A Pending JPWO2022186311A1 (https=) | 2021-03-04 | 2022-03-02 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240174622A1 (https=) |
| EP (1) | EP4303213A4 (https=) |
| JP (1) | JPWO2022186311A1 (https=) |
| KR (1) | KR20230154183A (https=) |
| AU (1) | AU2022228911A1 (https=) |
| CA (1) | CA3210294A1 (https=) |
| TW (1) | TW202302542A (https=) |
| WO (1) | WO2022186311A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4196175A4 (en) * | 2020-08-14 | 2025-07-30 | Clarity Pharmaceuticals Ltd | RADIOPHARMACEUTICAL COMPOUNDS, THEIR USES AND PROCESSES FOR THEIR PRODUCTION |
| CN116285684B (zh) * | 2023-05-15 | 2023-08-08 | 四川绚度眼视光科技有限公司 | 一种多功能超亲水涂层及其制备方法与应用 |
| CN116870176B (zh) * | 2023-08-03 | 2025-08-12 | 浙江大学 | PSMA靶向的PSMA-PARPi偶联物及制备方法和应用 |
| WO2025220711A1 (ja) * | 2024-04-17 | 2025-10-23 | 日本メジフィジックス株式会社 | 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物 |
| WO2026014283A1 (ja) * | 2024-07-09 | 2026-01-15 | 日本メジフィジックス株式会社 | 化合物、放射性標識化合物およびその製造方法、並びに放射性医薬組成物 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019075583A1 (en) * | 2017-10-22 | 2019-04-25 | British Columbia Cancer Agency Branch | NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN |
| WO2019190266A1 (ko) * | 2018-03-30 | 2019-10-03 | (주)퓨쳐켐 | 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품 |
| JP2019535754A (ja) * | 2016-11-23 | 2019-12-12 | キャンサー ターゲテッド テクノロジー エルエルシー | アルブミン結合ｐｓｍａ阻害剤 |
| WO2020106886A1 (en) * | 2018-11-20 | 2020-05-28 | Cornell University | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer |
| JP2020516611A (ja) * | 2017-04-05 | 2020-06-11 | コーネル ユニバーシティー | 画像化および抗腫瘍治療において有用な調整可能な薬物動態を有する三官能性構築物 |
| JP2020520902A (ja) * | 2017-05-24 | 2020-07-16 | イーテーエム イゾトーペン テクノロジエン ミュンヘン アーゲー | 新規ｐｓｍａ結合剤及びその使用 |
| WO2020220023A1 (en) * | 2019-04-26 | 2020-10-29 | Five Eleven Pharma Inc. | Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents |
| WO2021177390A1 (ja) * | 2020-03-04 | 2021-09-10 | 日本メジフィジックス株式会社 | 化合物及び放射性標識化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060228364A1 (en) | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| CA2760839C (en) | 2009-05-01 | 2019-02-12 | The Trustees Of The University Of Pennsylvania | Modified compstatin with peptide backbone and c-terminal modifications |
| CN108699108B (zh) | 2016-03-01 | 2022-04-08 | 国立大学法人千叶大学 | 放射性标记药物 |
| US11167050B2 (en) | 2017-09-26 | 2021-11-09 | National University Corporation Chiba University | Metal complex forming compound, metal complex compound formed thereof, radioactive drug containing the metal complex compound, and method of using and preparing the metal complex compound |
| BR112020023420A8 (pt) | 2018-05-17 | 2022-07-05 | Astellas Pharma Inc | Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante |
| SG11202103670XA (en) | 2018-10-10 | 2021-05-28 | Astellas Pharma Inc | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
| US12427209B2 (en) * | 2018-12-18 | 2025-09-30 | Provincial Health Services Authority | Dual mode 18F-labelled theranostic compounds and uses thereof |
| MX2021008230A (es) | 2019-01-07 | 2021-08-11 | Astellas Pharma Inc | Conjugado que comprende ligando y fragmento fab de anticuerpo ceacam5. |
-
2022
- 2022-03-02 AU AU2022228911A patent/AU2022228911A1/en active Pending
- 2022-03-02 KR KR1020237029291A patent/KR20230154183A/ko active Pending
- 2022-03-02 US US18/548,716 patent/US20240174622A1/en active Pending
- 2022-03-02 CA CA3210294A patent/CA3210294A1/en active Pending
- 2022-03-02 JP JP2023503935A patent/JPWO2022186311A1/ja active Pending
- 2022-03-02 EP EP22763364.1A patent/EP4303213A4/en active Pending
- 2022-03-02 WO PCT/JP2022/009003 patent/WO2022186311A1/ja not_active Ceased
- 2022-03-03 TW TW111107807A patent/TW202302542A/zh unknown
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019535754A (ja) * | 2016-11-23 | 2019-12-12 | キャンサー ターゲテッド テクノロジー エルエルシー | アルブミン結合ｐｓｍａ阻害剤 |
| JP2020516611A (ja) * | 2017-04-05 | 2020-06-11 | コーネル ユニバーシティー | 画像化および抗腫瘍治療において有用な調整可能な薬物動態を有する三官能性構築物 |
| JP2020520902A (ja) * | 2017-05-24 | 2020-07-16 | イーテーエム イゾトーペン テクノロジエン ミュンヘン アーゲー | 新規ｐｓｍａ結合剤及びその使用 |
| WO2019075583A1 (en) * | 2017-10-22 | 2019-04-25 | British Columbia Cancer Agency Branch | NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN |
| JP2021503490A (ja) * | 2017-10-22 | 2021-02-12 | プロビンシャル・ヘルス・サービシーズ・オーソリティＰｒｏｖｉｎｃｉａｌ Ｈｅａｌｔｈ Ｓｅｒｖｉｃｅｓ Ａｕｔｈｏｒｉｔｙ | 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物 |
| WO2019190266A1 (ko) * | 2018-03-30 | 2019-10-03 | (주)퓨쳐켐 | 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품 |
| WO2020106886A1 (en) * | 2018-11-20 | 2020-05-28 | Cornell University | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer |
| WO2020220023A1 (en) * | 2019-04-26 | 2020-10-29 | Five Eleven Pharma Inc. | Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents |
| WO2021177390A1 (ja) * | 2020-03-04 | 2021-09-10 | 日本メジフィジックス株式会社 | 化合物及び放射性標識化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202302542A (zh) | 2023-01-16 |
| WO2022186311A1 (ja) | 2022-09-09 |
| KR20230154183A (ko) | 2023-11-07 |
| CA3210294A1 (en) | 2022-09-09 |
| AU2022228911A1 (en) | 2023-09-21 |
| EP4303213A4 (en) | 2024-09-18 |
| EP4303213A1 (en) | 2024-01-10 |
| US20240174622A1 (en) | 2024-05-30 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230612 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20230616 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230616 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250213 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251008 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251211 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260310 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260422 |